Analysts Abandon Replimune: Stock Drops Sharply After Second FDA Rejection
Replimune shares plunged after the FDA issued a second rejection for its skin cancer drug RP1, prompting multiple analyst downgrades.
/ 4 items
#REPL↓
FDA Rejects Replimune’s Skin Cancer Drug for the Second Time
FDA again rejects Replimune’s skin cancer drug RP1, saying studies don’t prove it works; shares halted, setback for company.
Replimune Gets FDA Nod for RP1 Drug Resubmission
Replimune's RP1 melanoma treatment gets FDA acceptance for BLA resubmission with April 2026 review date. Wedbush upgrades stock to Outperform with $18 target as approval odds improve.
JPMorgan Downgrades Replimune Due to Regulatory Uncertainty
Replimune’s cancer drug, RP1, hit a snag after an FDA meeting. Quick approval is now unlikely due to regulatory uncertainty, causing the stock to drop sharply (39% Thursday). The company is seeking a new way forward for the melanoma treatment.